To investigate the association between taking herbal medicine (HM) containing aristolochic acid (AA) and the risk of primary liver cancer (PLC) among patients with hepatitis C virus (HCV)-infection.
This is a prospective study for the long-term follow up of a nationwide population-based cohort of patients aged 18 years or older diagnosed with HCV infection during 1997-2010. A total of 223,467 HCV-infected patients were identified using the National Health Insurance Research Database in Taiwan. The use of HM containing AA was evaluated among patients who had visited traditional Chinese medicine (TCM) clinics beginning from 1997 to one year prior to the diagnosis of PLC or dates censored (2003). We tracked each individual patient from 1997 to 2013 to identify incident cases of PLC since 1999.
During the follow-up period of 3,052,132 person-years, we identified 25,502 PLC cases; this corresponding to an overall incidence rate was 835.5 PLCs per 100,000 person-years. The adjusted hazard ratios (HRs) were 1.21 (95% confidence interval [CI], 1.18 to 1.24), 1.48 (95% CI, 1.37 to 1.59), 1.50 (95% CI, 1.34 to 1.68), and 1.88 (95% CI, 1.61 to 2.19) for estimated AA usage groups: 1 to 250, 251 to 500, 501 to 1,000, and more than 1,000 mg, respectively, relative to no AA exposure (reference group).
The current findings suggest that among HCV positive patients, increasing exposure to AA poses an increased risk of acquiring PLC.
AA may increase the risk of PLC in HCV positive populations.